Search

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.

… Monday, July 11, 2022 Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from Memorial Sloan Kettering Cancer Center (MSK) published in JAMA Surgery .  (

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.

… Sunday, March 23, 2008 Research led by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice. The study’s results are published in the March 23 online edition

Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.

… Monday, April 24, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Anaeze Offodile II, MD, MPH , will join the institution as Chief Strategy Officer (CSO) on May 1. Dr. Offodile — a double board-certified physician with clinical expertise in oncologic reconstruction, a health services

Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.

… Monday, August 5, 2019 Summary Pexidartinib is the first drug approved specifically to treat the rare joint tumor tenosynovial giant cell tumor, which is also known as pigmented villonodular synovitis. On August 2, the US Food and Drug Administration announced that it had approved pexidartinib (Turalio

Learn how experts at MSK who helped develop CAR T cell therapy to fight cancer are making the treatment stronger, safer, more durable and accessible to more people.

… Tuesday, November 7, 2023 Giving one dose of a treatment that will stay in a patient’s body to help it continue to fight cancer may seem like mission impossible. But it’s not. This type of immunotherapy , called CAR T cell therapy , is one of the most exciting fields in cancer treatment today. What Are

Dinshaw J. Patel, a Member in Sloan Kettering Institute's Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.

… Wednesday, July 1, 2009 Summary Dinshaw J. Patel, a Member in Sloan Kettering Institute’s Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April. Dinshaw J. Patel ,

MSK researchers discover a possible reason why people with kidney cancer respond better to treatments such as immunotherapy if they are obese.

… Friday, December 20, 2019 Summary Obesity increases the risk of developing kidney cancer . However, obese people seem to do better after treatment compared with people of normal weight. MSK researchers have discovered that fat surrounding kidney tumors may play a key role in the effectiveness of kidney

MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。

… Friday, December 20, 2019 总结 肥胖会增加患 肾癌 的风险。然而，与正常体重的人相比，肥胖的人接受治疗的效果似乎更好。MSK 斯隆的研究人员发现，肾脏肿瘤周围的脂肪可能对肾癌治疗的有效性起关键作用。 长期以来，肾癌专家一直对这种疾病与肥胖之间的奇怪关系感到困惑。尽管肥胖人群患癌症的风险增加，但他们比非肥胖人群在疾病中存活的几率高。 纪念斯隆凯特琳癌症中心的研究人员多年来一直在研究这一被称为“肥胖悖论”的现象。2014 年，由流行病学家 Helena Furberg 和泌尿肿瘤外科医生 Ari Hakimi 领导的一个研究小组发现，由于肥胖人群的一个促癌基因活性较低， 其肿瘤的生长速度可能会减慢

African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.

… Monday, April 17, 2023 The disparities are disturbing: Black men and women are more likely to get colorectal cancer than any other racial group in the United States. They also are 40% more likely to die from it than other racial groups. There are many possible explanations , including differences in

It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.

… Wednesday, July 2, 2025 The latest treatments for  prostate cancer have become more effective, convenient, and personalized for patients than ever before. Among the most powerful tools is  radiation therapy , which can be delivered in multiple ways to target prostate cancer with precision, while minimizing